How are ADAs to eculizumab managed?

Nov 25, 2008 ... Eculizumab, a terminal complement inhibitor, improves anaemia in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol 2008;142(2): ... Mar 6, 2012 ... For these very small children, eculizumab should be considered first. In larger children who can be treated with plasma exchange, treatment with ... Soliris was approved by the U.S. Food and Drug Administration in 2019 for the treatment of adults with NMOSD who are positive for anti-AQP4 antibodies. The ... Initially 900 mg once weekly for 4 weeks, then increased to 1.2 g once weekly for 1 week, followed by maintenance 1.2 g every 12–16 days, consider ... Develop highly selective and sensitive PK and ADA assays for the monoclonal antibody drug eculizumab (Soliris) using ready-made anti-idiotypic antibodies. Nov 18, 2022 ... Early eculizumab withdrawal in patients with atypical hemolytic uremic syndrome in native kidneys is safe and cost-effective: results of the CUREiHUS study This medication helps to block the decrease in red blood cells and can improve the symptoms of anemia (such as tiredness, shortness of breath) and decrease the ... Oct 3, 2024 ... - Soliris is a complement inhibitor indicated for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis; atypical ... Sep 29, 2023 ... What are the side effects of Soliris? · headache · diarrhea · high blood pressure (hypertension) · common cold (upper respiratory infection ) ... Why is Soliris authorised in the EU? Soliris was shown to benefit patients with these rare diseases. The safety profile was similar for all the diseases and was ...